4.3 Article

Antitumour necrosis factor alpha treatment in Crohn's disease: long-term efficacy, side effects and need for surgery

Journal

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
Volume 57, Issue 8, Pages 921-929

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/00365521.2022.2042592

Keywords

Crohn's disease; inflammatory bowel disease; anti-TNF; long-term follow-up; treatment failure; drug survival; surgical resection

Funding

  1. Ostfold Hospital Trust

Ask authors/readers for more resources

This study aims to evaluate the long-term efficacy and side effects of anti-TNF therapy in patients with CD. The results show that only one in four patients achieved long-term complete remission, and one in four patients had to discontinue therapy. Some patients required surgical resection before and after treatment.
Objectives To examine the long-term efficacy and side effects of antitumour necrosis factor alpha (anti-TNF) therapy in patients with Crohn's disease (CD), the need for surgery and the clinical outcome after discontinuing anti-TNF therapy. Material and methods Data were collected from the inflammatory bowel disease (IBD)-TNF register at ostfold Hospital Trust. Clinical and sociodemographic data were recorded for patients initiating anti-TNF therapy from January 2000 until December 2011. Follow-up was conducted until December 2017. Results Complete remission (CR) was achieved in 40/154 (26%) patients at the last follow-up (median follow-up time 10 years). A total of 40 (26%) patients had to discontinue treatment due to serious side effects, and malignancy was recorded in 10 (6.5%) patients. Surgical resection was performed in 55 (36%) patients during follow-up. Patients with Montreal phenotype B2 before anti-TNF therapy were estimated to have a 2.54-fold greater risk of surgery than patients with phenotype B1 (p = .001). Of those with phenotype B1 before anti-TNF therapy, 19 (24%) of them developed stenosis in need of surgical resection ('phenotype migration'). In patients followed up after discontinuing anti-TNF therapy (n = 89, median observational time six years), CR was achieved in most patients. Conclusions Long-term complete remission was achieved in only one in four patients receiving anti-TNF therapy, and one in four patients had to discontinue therapy due to side effects. Despite anti-TNF therapy, one in four patients with a baseline luminal disease phenotype needed subsequent surgical resection.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available